Selzentry Advisory Committee To Weigh Virologic Resistance Vs. Adverse Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer wants to expand the indication of its HIV drug to treatment-naive patients, but FDA wants the panel's advice on what the standards for such a claim should be.
You may also be interested in...
Selzentry Patient Population Needs Further Definition, Advisory Panel Urges
Determining the effect of Pfizer's Selzentry (maraviroc) in subpopulations of HIV patients was the theme of recommendations by the Antiviral Drugs Advisory Committee for post-marketing studies Oct. 8
Selzentry Patient Population Needs Further Definition, Advisory Panel Urges
Determining the effect of Pfizer's Selzentry (maraviroc) in subpopulations of HIV patients was the theme of recommendations by the Antiviral Drugs Advisory Committee for post-marketing studies Oct. 8
Selzentry Faces Assay Challenge Even After Advisory Committee Thumbs Up
FDA will wrestle with how to include an unapproved diagnostic test in expanded labeling for Pfizer's HIV drug.